

1. Sales January to June 2007 and 2006

	2007	2006	% change	
	CHF m	CHF m	In CHF	In local currencies
January – June				
Pharmaceuticals Division	18,268	15,577	+17	+18
Roche Pharmaceuticals	11,367	9,670	+18	+16
Genentech	5,227	4,223	+24	+28
Chugai	1,674	1,684	-1	+7
Diagnostics Division	4,559	4,272	+7	+5
Roche Group	22,827	19,849	+15	+15

2. Quarterly local sales growth by Division in 2006 and 2007

	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006
Pharmaceuticals Division	+25	+22	+20	+16
Roche Pharmaceuticals	+25	+20	+18	+13
Genentech	+33	+37	+30	+26
Chugai	+2	+2	+11	+2
Diagnostics Division	+6	+5	+6	+5
Roche Group	+20	+18	+17	+13

3. Quarterly sales by Division in 2006 and 2007

CHF millions	Q2 2006	Q3 2006	Q4 2006	Q1 2007	Q2 2007
Pharmaceuticals Division	7,838	8,335	9,382	9,142	9,126
Roche Pharmaceuticals	4,849	5,251	5,745	5,702	5,665
Genentech	2,167	2,299	2,603	2,547	2,680
Chugai	822	785	1,034	893	781
Diagnostics Division	2,181	2,143	2,332	2,216	2,343
Roche Group	10,019	10,478	11,714	11,358	11,469

4. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD June 2007: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	2,704	16%	1,424	13%	86	4%	1,194	22%
Herceptin	2,382	30%	786	5%	81	24%	1,515	51%
Avastin	1,909	40%	1,346	34%	3	-	560	57%
Tamiflu	1,316	39%	466	75%	244	46%	606	16%
NeoRecormon/Epogin	1,066	-4%	-	-	288	-9%	778	-2%
CellCept	979	10%	467	11%	16	17%	496	10%
Pegasys	807	11%	211	0%	25	-21%	571	18%
Xeloda	549	16%	198	13%	13	4%	338	19%
Lucentis	524	4022%	524	4022%	-	-	-	-
Tarceva	503	37%	250	4%	-	-	253	107%
Bonviva/Boniva	374	127%	255	80%	-	-	119	484%
Xenical	339	-8%	50	-17%	-	-	289	-6%
Xolair	284	14%	284	14%	-	-	-	-
Valcyte/Cymevene	261	17%	126	15%	-	-	135	19%
Nutropin	239	1%	232	1%	-	-	7	2%
Pulmozyme	231	9%	132	11%	-	-	99	7%
Kytril	205	-17%	66	-32%	64	6%	75	-17%
Rocephin	204	-4%	13	-22%	28	4%	163	-4%
Activase/TNKase	202	18%	182	21%	-	-	20	-5%
Neutrogen	195	11%	-	-	195	11%	-	-

¹ Roche Pharmaceuticals, Genentech and Chugai combined ² versus YTD June 2006

5. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2006 and 2007

	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006
MabThera/Rituxan	13%	17%	17%	16%
Herceptin	72%	58%	36%	25%
Avastin	55%	49%	41%	39%
Tamiflu	141%	43%	47%	25%
NeoRecormon/Epogin	-4%	-1%	-3%	-5%
CellCept	7%	7%	7%	14%
Pegasys	1%	6%	15%	7%
Xeloda	13%	16%	14%	18%
Lucentis	-	-	-	1964%
Tarceva	110%	71%	44%	31%
Bonviva/Boniva	929%	251%	132%	123%
Xenical	-1%	6%	-10%	-6%
Xolair	34%	23%	16%	13%
Valcyte/Cymevene	26%	30%	15%	19%
Nutropin	5%	8%	5%	-2%
Pulmozyme	8%	11%	4%	15%
Kytril	0%	-10%	-16%	-18%
Rocephin	-35%	-32%	-7%	-2%
Activase/TNKase	9%	14%	15%	20%
Neutrogin	1%	7%	11%	12%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth¹ US in 2006 and 2007

	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006
MabThera/Rituxan	9%	15%	13%	12%
Herceptin	40%	29%	7%	3%
Avastin	34%	36%	34%	33%
Tamiflu	229%	33%	-8%	196%
NeoRecormon/Epogin	-	-	-	-
CellCept	9%	13%	3%	18%
Pegasys	-11%	-6%	6%	-5%
Xeloda	11%	16%	2%	23%
Lucentis	-	-	-	1964%
Tarceva	37%	27%	9%	-1%
Bonviva/Boniva	818%	205%	83%	77%
Xenical	6%	11%	-24%	-8%
Xolair	34%	23%	16%	13%
Valcyte/Cymevene	32%	38%	8%	20%
Nutropin	5%	8%	5%	-2%
Pulmozyme	7%	8%	6%	17%
Kytril	5%	-26%	-28%	-36%
Rocephin	-89%	-94%	-34%	-7%
Activase/TNKase	9%	11%	18%	24%
Neutrogin	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2006 and 2007

	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006
MabThera/Rituxan	3%	1%	1%	6%
Herceptin	33%	26%	23%	25%
Avastin	-	-	-	-
Tamiflu	6485%	36%	55%	-93%
NeoRecormon/Epogin	-22%	-12%	-17%	-3%
CellCept	19%	14%	21%	14%
Pegasys	-34%	-37%	-38%	-5%
Xeloda	-9%	-9%	3%	6%
Lucentis	-	-	-	-
Tarceva	-	-	-	-
Bonviva/Boniva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Nutropin	-	-	-	-
Pulmozyme	-	-	-	-
Kytril	4%	5%	7%	5%
Rocephin	2%	4%	4%	5%
Activase/TNKase	-	-	-	-
Neutrogen	1%	7%	11%	12%

¹ Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2006 and 2007

	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006	Q2 2007 vs. Q2 2006
MabThera/Rituxan	20%	22%	23%	21%
Herceptin	104%	87%	61%	43%
Avastin	162%	101%	63%	52%
Tamiflu	49%	52%	76%	-48%
NeoRecormon/Epogin	6%	5%	3%	-6%
CellCept	4%	0%	10%	10%
Pegasys	11%	19%	23%	13%
Xeloda	16%	17%	22%	16%
Lucentis	-	-	-	-
Tarceva	867%	211%	125%	94%
Bonviva/Boniva	-	885%	658%	400%
Xenical	-3%	5%	-7%	-6%
Xolair	-	-	-	-
Valcyte/Cymevene	19%	21%	21%	17%
Nutropin	10%	14%	0%	4%
Pulmozyme	10%	16%	1%	13%
Kytril	-9%	-5%	-15%	-19%
Rocephin	-8%	-10%	-5%	-2%
Activase/TNKase	7%	31%	-6%	-4%
Neutrogen	-	-	-	-

¹ Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales¹ in 2006 and 2007

CHF millions	Q2 2006	Q3 2006	Q4 2006	Q1 2007	Q2 2007
MabThera/Rituxan	1,202	1,177	1,314	1,309	1,395
Herceptin	952	1,009	1,105	1,168	1,214
Avastin	713	741	832	923	986
Tamiflu	360	669	997	865	451
NeoRecormon/Epogin	565	535	592	522	544
CellCept	437	466	485	476	503
Pegasys	374	350	393	400	407
Xeloda	234	239	260	267	282
Lucentis	13	192	273	263	261
Tarceva	195	211	235	243	260
Bonviva/Boniva	92	142	179	170	204
Xenical	182	160	170	163	176
Xolair	133	135	145	136	148
Valcyte/Cymevene	113	126	139	124	137
Nutropin	126	118	132	117	122
Pulmozyme	103	108	116	111	120
Kytril	124	127	117	105	100
Rocephin	106	96	104	100	104
Activase/TNKase	90	89	95	96	106
Neutrogen	95	91	100	96	99

¹ Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales¹ in US in 2006 and 2007

CHF millions	Q2 2006	Q3 2006	Q4 2006	Q1 2007	Q2 2007
MabThera/Rituxan	675	650	737	682	742
Herceptin	400	374	398	383	403
Avastin	527	539	606	657	689
Tamiflu	108	361	275	147	319
NeoRecormon/Epogin	-	-	-	-	-
CellCept	215	241	264	217	250
Pegasys	115	107	122	104	107
Xeloda	90	90	111	89	109
Lucentis	13	192	273	263	261
Tarceva	129	123	132	125	125
Bonviva/Boniva	78	122	144	120	135
Xenical	28	25	27	24	26
Xolair	133	135	145	136	148
Valcyte/Cymevene	59	68	77	56	70
Nutropin	123	115	127	114	118
Pulmozyme	58	62	66	65	67
Kytril	43	56	39	39	27
Rocephin	8	6	2	6	7
Activase/TNKase	78	78	81	88	94
Neutrogen	-	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales¹ in Japan in 2006 and 2007

CHF millions	Q2 2006	Q3 2006	Q4 2006	Q1 2007	Q2 2007
MabThera/Rituxan	48	49	56	38	48
Herceptin	38	40	46	36	45
Avastin	-	-	-	-	3
Tamiflu	9	57	173	246	-2
NeoRecormon/Epogin	182	147	194	124	164
CellCept	8	8	9	7	9
Pegasys	16	14	15	10	15
Xeloda	7	7	7	6	7
Lucentis	-	-	-	-	-
Tarceva	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Nutropin	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Kytril	36	34	40	29	35
Rocephin	16	13	17	12	16
Activase/TNKase	-	-	-	-	-
Neutrogen	95	91	100	96	99

¹ Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2006 and 2007

CHF millions	Q2 2006	Q3 2006	Q4 2006	Q1 2007	Q2 2007
MabThera/Rituxan	479	478	521	589	605
Herceptin	514	595	661	749	766
Avastin	186	202	226	266	294
Tamiflu	243	251	549	472	134
NeoRecormon/Epogin	383	388	398	398	380
CellCept	214	217	212	252	244
Pegasys	243	229	256	286	285
Xeloda	137	142	142	172	166
Lucentis	-	-	-	-	-
Tarceva	66	88	103	118	135
Bonviva/Boniva	14	20	35	50	69
Xenical	154	135	143	139	150
Xolair	-	-	-	-	-
Valcyte/Cymevene	54	58	62	68	67
Nutropin	3	3	5	3	4
Pulmozyme	45	46	50	46	53
Kytril	45	37	38	37	38
Rocephin	82	77	85	82	81
Activase/TNKase	12	11	14	8	12
Neutrogin	-	-	-	-	-

¹ Roche Pharmaceuticals